Nuvalent, Inc. - Class A (NUVL)
NUVL moved a median of -0.21% 30 minutes after news, and +0.10% by the close. How NUVL actually reacts to news — the realized, point-in-time move the market made, measured across 488 labeled events over the last three years with zero look-ahead.
NUVL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 41% | 458 |
| 30-min | -0.21% | 43% | 459 |
| 60-min | -0.00% | 50% | 459 |
| to close | +0.10% | 56% | 459 |
| Middle 50% of NUVL reactions | -0.95% to +0.51% |
|---|---|
| Median reaction (30-min) | -0.21% |
| Measured reactions | 488 |
Half of all Nuvalent, Inc. - Class A news events land between -0.95% and +0.51% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NUVL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -1.26% | 27% | -0.07% |
| Analyst downgrades | 40 | +0.07% | 83% | +0.10% |
| Coverage initiations | 44 | +0.42% | 71% | +0.04% |
| Rating reiterations | 69 | -0.04% | 48% | +0.20% |
| Price-target raises | 23 | +0.59% | 61% | +0.61% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how NUVL ranks against every other measured name →
That’s how NUVL usually reacts — get an email when it moves on news →Email me when NUVL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NUVL's baseline. Nothing else.
Recent NUVL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Nuvalent, Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Halper Sadeh LLC is Investigating Whether ATAI, CCRN, NUVL are Obtaining Fair Deals for their Shareholders | Press release | GlobeNewswire | — | — | |
| Form 8-K Nuvalent, Inc. For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POSASR Nuvalent, Inc. | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Nuvalent, Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Halper Sadeh LLC is Investigating Whether DAN, ESI, NUVL, BOLD are Obtaining Fair Deals for their Shareholders | Press release | GlobeNewswire | +0.00% | -0.01% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC), | Press release | GlobeNewswire | +0.00% | +0.02% | |
| Are ROKU, SLP, NUVL, DAN Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.01% | -0.04% | |
| Form 8-K Nuvalent, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | -0.07% | |
| NUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSK | Press release | GlobeNewswire | -0.07% | -0.02% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC) | Press release | GlobeNewswire | +0.02% | +0.06% | |
| Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.01% | +0.04% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), SUNation Energy, Inc. (Nasdaq – SUNE), Organon & Co. (NYSE – OGN), Taylor Morrison Home Corporation (NYSE – TMHC) | Press release | GlobeNewswire | -0.08% | +0.04% | |
| Form 8-K Nuvalent, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | +0.36% | |
| NUVL Stock Alert: Halper Sadeh LLC is Investigating Whether Nuvalent, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | +0.06% | +0.36% | |
| Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC | Press release | PR Newswire | -0.56% | +0.94% | |
| Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting | Press release | PR Newswire | -0.48% | +0.12% | |
| Form 10-Q Nuvalent, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.24% | -1.64% | |
| Form 8-K Nuvalent, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.24% | -1.64% | |
| Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | Press release | PR Newswire | -0.24% | -1.64% | |
| Form ARS Nuvalent, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.11% | -1.74% | |
| Form DEF 14A Nuvalent, Inc. For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | -0.11% | -1.74% | |
| Form DEFA14A Nuvalent, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.11% | -1.74% | |
| Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting | Press release | PR Newswire | -0.39% | -0.13% | |
| New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 | Press release | PR Newswire | -1.49% | +0.78% | |
| Form 8-K Nuvalent, Inc. For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | +0.35% | |
| Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC | Press release | PR Newswire | +0.54% | -0.35% | |
| Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 | Press release | PR Newswire | -0.28% | -1.49% | |
| Form 10-K Nuvalent, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.31% | -1.79% | |
| Form 8-K Nuvalent, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.31% | -1.79% | |
| Form S-8 Nuvalent, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.31% | -1.79% | |
| Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | PR Newswire | -2.31% | -1.79% | |
| Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | PR Newswire | +1.54% | -3.96% | |
| Form 8-K Nuvalent, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -2.42% | +5.86% | |
| Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones | Press release | PR Newswire | -1.37% | -4.96% | |
| Form S-3ASR Nuvalent, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +1.00% | +1.81% | |
| Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +1.00% | +1.81% | |
| Form 8-K Nuvalent, Inc. For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | -1.53% | |
| Form 8-K Nuvalent, Inc. For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +1.35% | +0.39% | |
| Nuvalent Appoints Ron Squarer to Board of Directors | Press release | PR Newswire | +1.35% | +0.39% | |
| Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference | Press release | PR Newswire | -0.65% | -0.85% | |
| Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders | Press release | PR Newswire | +0.00% | +0.74% | |
| Form 8-K Nuvalent, Inc. For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | -0.07% | +0.82% | |
| Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Press release | PR Newswire | -0.07% | +0.82% | |
| Nuvalent Announces Pricing of Public Offering of Common Stock | Press release | PR Newswire | +2.10% | +2.39% | |
| Form 8-K Nuvalent, Inc. For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | +6.06% | +15.76% | |
| Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | Press release | PR Newswire | +6.06% | +15.76% | |
| Nuvalent Announces Public Offering of Common Stock | Press release | PR Newswire | -0.67% | -1.48% | |
| Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib | Press release | PR Newswire | +6.06% | +15.76% | |
| Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer | Press release | PR Newswire | +0.82% | +1.73% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NUVL section they belong to.
Where else NUVL is measured.
NUVL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Nuvalent, Inc. - Class A's median reaction calculated?
Every labeled NUVL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 488 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of NUVL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NUVL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.